Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."